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L
ung cancer is the leading cause of cancer-related mortality worldwide. The cure rate remains Ͻ 15% despite improvements in surgery, radiotherapy, and chemotherapy. 1 Nevertheless, the management of patients with lung cancer has improved recently. A complete recovery or prolonged survival is now achieved in some patients with non-small cell lung cancer (NSCLC). [2] [3] [4] [5] Moreover, many new anticancer medications are currently under clinical evaluation, especially in patients with advanced disease. 6, 7 Survival rates in critically ill patients with cancer have improved over the last decade. 8 -10 However, ICU admission is widely believed to be of little avail in patients with lung cancer with acute life-threatening events, most notably those with acute respiratory failure (ARF) requiring mechanical ventilation (MV). 11, 12 In addition, these patients usually exhibit cardiac and pulmonary comorbidities related to smoking. 13 Nevertheless, survival data are scant. 11,12,14 -16 Data on current survival rates and factors that influence survival would help to make appropriate management decisions. The objective of this study was to measure survival and to identify risk factors for hospital mortality in a large cohort of patients with lung cancer admitted to two ICUs.
Hô pital Saint-Louis, Université Paris 7, Assistance Publique, Hô pitaux de Paris, France. The INCA is a 200-bed teaching hospital for patients with cancer. Its ICU is a 10-bed medicalsurgical unit. The Hô pital Saint-Louis is a 650-bed hospital with 330 beds in hematology and oncology wards and a 12-bed medical ICU. The organization and admission policies of both ICUs have been described elsewhere. 17, 18 As a rule, only patients for whom potentially lifespan-extending treatment is available are considered for ICU admission. Decisions to forego life-sustaining treatment (DFLSTs) are made in the ICU when acute illness persists or worsens despite full-code management. The study was supported by institutional funds. The institutional review boards of both institutions approved the study and waived the need for informed consent. The study did not interfere with patient management decisions.
Selection of Participants, Data Collection, and Definitions
Patients from the INCA were included between May 2000 and April 2006. TNM classification, histopathologic classification, and previous treatments were retrieved from patient charts and institution database. All other data were collected prospectively. Patients from the Hô pital Saint-Louis were admitted to the ICU between January 2000 and June 2005. Their charts were reviewed retrospectively.
All adults (age Ն 18 years) who had a definite diagnosis of lung cancer and were admitted to the ICU during the study period were potentially eligible. Cancer remission for Ͼ 5 years, ICU stay Ͻ 24 h, and ICU admission for routine postoperative care were exclusion criteria. In patients with multiple ICU admissions, only the first admission was considered.
The following variables were collected on the first ICU day: age, gender, Simplified Acute Physiology Score (SAPS) II, 19 Logistic Organ Dysfunction (LOD) score, 20 main reason for ICU admission, weight loss Ͼ 10% of usual body weight in the last 3 months, and comorbidities. We used the Adult Comorbidity Evaluation-27 (ACE-27) to determine the overall comorbidity score based on the severity of organ decompensation (none, mild, moderate, or severe) and on the prognostic impact of a wide range of comorbid diseases and conditions. 21 The type of cancer, cancer status (controlled/remission, newly diagnosed, or progression/recurrence) and extent, anticancer treatments, and performance status (Eastern Cooperative Oncology Group scale) 22 during the week before hospital admission were also assessed. Disease extent was evaluated by the TNM classification, 23 with limited disease being defined as stage I-IIIa and extensive disease as stage IIIb-IV. During the ICU stay, the need for vasopressors (any dose of norepinephrine or epinephrine, Ն 5 g/kg/min of dopamine or dobutamine), conventional or noninvasive MV for Ͼ 24 h, reasons for MV, development of acute organ failures, and anticancer treatments were recorded. Cancer was considered to be a reason for MV in patients with bilateral involvement, carcinomatous lymphangitis, or tumor masses resulting in airway obstruction or atelectasis. Sepsis was diagnosed using the criteria developed at the American College of Chest Physicians/Society of Critical Care Medicine consensus conferences 24 and infection using criteria from the Centers for Diseases Control and Prevention. 25 Community-acquired pneumonia was defined according to criteria of the American Thoracic Society established in 2001. 26 ARDS was defined according to the American-European consensus conference. 27 Individual organ failure was defined as a LOD score Ն 1 point for each system. 20 Patients were followed up until hospital death or discharge. The primary evaluation criterion was in-hospital death from any cause.
Data Presentation and Statistical Analysis
Standard descriptive statistics were computed. Continuous variables were reported as mean Ϯ SD or median (25 to 75% interquartile range). Univariate and multivariate logistic regression were used to identify factors associated with hospital mortality. Linearity between each continuous variable (age, SAPS II score, and number of organ failures) and the dependent variable was demonstrated using locally weighted scatterplot smoothing (lowess). 28 Variables yielding p values Ͻ 0.2 by univariate analysis were entered in a forward multivariate logistic regression analysis, as well as variables considered clinically relevant. Two analyses were performed, one in the entire study population, and other in the subpopulation of patients who received MV. In both multivariate analyses, a base model including cancer status and number of organ failures was created. These variables were chosen because they had been previously shown to strongly influence mortality in ICU patients with cancer. 29 -31 The other covariates were entered into the model with critical entry and removal p values of 0.05 and 0.1, respectively. Effects on covariate coefficients were also considered. Odds ratios (ORs) with their 95% confidence intervals (CIs) were computed. Colinearity and interactions were tested. The SAPS II score was not initially entered in multivariate analyses because it encompassed other study variables such as age and variables used to define organ failures. 19 The area under the receiver operating characteristic curve was used to evaluate the ability of the model to discriminate between patients who survived and those who died. 32 The Hosmer-Lemeshow goodness-of-fit test was used to evaluate agreement between the observed and expected numbers of survivors and decedents across all strata of probabilities of death (calibration). 28 With this test, p Ͼ 0.05 indicates a good fit for the model. Two-tailed p values Ͻ 0.05 were considered statistically significant.
Results

Patient Characteristics
The study included 152 patients: 98 patients (64%) from INCA and 54 patients (36%) from Hô pital Saint- Louis. Nine patients from Hô pital Saint-Louis were excluded due to missing data, leaving 143 patients for the study. Baseline patient characteristics were similar in the two institutions ( Table 1 ). The main reasons for ICU admission are depicted in Table 2 . Infection was present at ICU admission in 86 patients (60%), with the main categories being community-acquired pneumonia (n ϭ 46, 53%), nosocomial pneumonia (n ϭ 21, 24%), abdominal infection (n ϭ 4, 5%), and urinary tract infection (n ϭ 3, 3%). During the ICU stay, the following organ failures were diagnosed: respiratory (n ϭ 102, 71%), cardiovascular (n ϭ 82, 57%), renal (n ϭ 34, 24%), neurologic (n ϭ 23, 16%), hematologic (n ϭ 22, 15%), and hepatic (n ϭ 5, 3%). Only five patients (3%) had neutropenia. Eighteen patients (13%) received emergency anticancer treatment while in the ICU (chemotherapy alone [n ϭ 12], radiation therapy alone [n ϭ 3], or combined therapy [n ϭ 3]). Ten patients had small cell lung cancer (SCLC) and 8 had NSCLC. Indications for emergency anticancer treatment were airway infiltration/obstruction (n ϭ 13), spinal cord compression (n ϭ 2), superior vena cava syndrome (n ϭ 1), paraneoplastic vasculitis (n ϭ 1), and carcinoid syndrome (n ϭ 1).
Outcome Analysis
In the 152 included patients, ICU and hospital mortality rates were 44% and 60%, respectively. ICU mortality was similar in the two institutions (47% [46 of 98 patients] vs 39% [21 of 54 patients], p ϭ 0.432), whereas hospital mortality was slightly higher at the INCA (65% [64 of 98 patients]) than at the Hô pital St. Louis (50%, 27 of 54 patients; p ϭ 0.095). Of the nine excluded patients, seven died in the ICU and two were discharged alive from the hospital. DFLSTs were made in 42 patients (28%) after a median of 4 days (range, 2 to 10 days) in the ICU, and 4 days (range, 2 to 10 days) prior to hospital death or discharge. The rates of DFLSTs were similar in the two institutions (29% [28 of 98 patients] vs 26% [14 of 54 patients], p ϭ 0.873).
Outcome data of the 143 study patients are reported in Table 1 . Overall ICU and hospital mortality rates were 42% and 59%, respectively. Age was similar in survivors and decedents (62.6 Ϯ 10.0 years vs 60.3 Ϯ 9.7 years, p ϭ 0.181), as was the number of hospital days prior to ICU admission (2 days [range, 1 to 5 days] vs 1 day [range, 0 to 7 days], p ϭ 0.388). As expected, patients who died had higher SAPS II score (53.7 Ϯ 21.8 vs 38.4 Ϯ 17.2, p Ͻ 0.001) and Table 3 . Age, cancer extent, performance status, cancer status, airway obstruction by cancer, moderate or severe comorbidity score, infection at ICU admission, need for MV or vasopressors, and number of organ failures during the ICU stay were entered in the multivariate analysis. A moderate or severe comorbidity score, cancer recurrence or progression, a larger number of organ failures, and airway obstruction due to cancer invasion or compression independently predicted increased hospital mortality ( Table  3 ). The final model showed good discrimination and calibration. The SAPS II score, DFLSTs, and type of cancer (NSCLC ϭ 0; SCLC ϭ 1) were then forced into the final model. As expected DFLSTs were selected (p ϭ 0.001) but the SAPS II score (p ϭ 0.455) and type of cancer (p ϭ 0.338) were not selected. In general, the effects of the other covariates on the dependent variable remained unchanged.
Of the 59 patients who were discharged home, 48 patients (81%) were alive and 11 patients (19%) were dead at last follow-up. Median follow-up duration was 79 days (range, 15 to 182 days).
Patients Requiring MV
MV was required in 100 patients, either within 24 h of ICU admission (n ϭ 94) or later on during the ICU stay (n ϭ 6). Conventional MV was used initially in 87 patients, and noninvasive MV was used in 13 patients, of whom 7 patients subsequently required conversion to conventional MV. The reasons for MV were pulmonary sepsis (n ϭ 60), acute decompensation of COPD (n ϭ 14), coma (n ϭ 12), extrapulmonary sepsis (n ϭ 8), pulmonary embolism (n ϭ 5), cardiac pulmonary edema (n ϭ 3), cardiopulmonary arrest (n ϭ 3), and miscellaneous (n ϭ 12); some patients had more than one reason for MV. Lung cancer was considered a reason for MV in 38 patients. Diagnostic criteria for ARDS were met by 59 patients. Median MV duration was 7 days (range, 3 to 13 days ICU and hospital mortality rates in the subgroup treated with MV were 56% and 69%, respectively. Table 4 reports the results of univariate analysis in 
Discussion
Many patients with lung cancer require admission to the ICU during the course of the disease. That ICU admission is beneficial in the postoperative period after pulmonary resection for lung cancer is well established. However, when acute life-threatening complications develop, most notably ARF, oncologists and intensivists are often doubtful about the wisdom of ICU admission. ARF in these patients is usually considered a consequence of advanced disease that is not responsive to supportive care. To the best of our knowledge, the present study is the largest cohort of critically ill patients with lung cancer investigated to date. The study population consisted of patients from two large centers whose ICU triage policies are based on extensive experience with cancer patients.
In previous studies 11, 12, 14, 15 of critically ill patients with lung cancer, mortality rates ranged from 75 to 91%. Very recently, Reichner et al 16 reported a 60% mortality rate in a study with 47 patients. Similarly, we found somewhat lower mortality rates, 59% overall and 69% in patients who needed MV. Over the last decade, advances in both oncology and intensive care have translated into better survival rates in ICU patients with cancer. In addition, improved selection of patients likely to benefit from ICU management may have contributed to the higher survival rates in our patients. Finally, few patients had treatment-related complications; notably, only five patients had neutropenia.
Together with the number of organ failures and the presence of cancer recurrence or progression, the severity of comorbidities was a major determinant of increased mortality in our study. Piccirillo and colleagues 13 reported that 69% of patients with lung cancer had comorbidities, and the highest levels of comorbidity were found in these patients. 33 Moreover, severe comorbidities as evaluated by ACE-27 score were associated with higher 6-month mortality rates in critically ill patients with cancer. 34 Not surprisingly, ARF due to cancer invasion or compression was the strongest predictor of increased mortality, in keeping with a recent study. 29 In particular, all patients with SCLC (generally highly responsive to chemotherapy or radiation therapy) in whom cancer was considered a reason for MV died within 3 months after ICU admission, despite receiving anticancer treatment in the ICU. In a study by Jennens et al 15 of five patients with SCLC who required MV and received chemotherapy in the ICU, three patients had extensive disease, failed to respond to chemotherapy, and died shortly after ICU admission. Moreover, cancer involvement is associated with failure of noninvasive MV. 35 All these factors may explain the infrequent use of noninvasive ventilation in our patients. In a retrospective study 12 of 81 patients receiving MV, airway obstruction was not associated with a lower rate of weaning from MV. However, hospital mortality was 85.2%, and factors that predicted death were not evaluated. 12 The present study has several limitations. Although standard definitions were used, biases related to differences in data collection between the centers cannot be ruled out. In many patients, long-term follow-up was not available. Although we focused on predictors of short-term mortality, we acknowledge this aspect as an important shortcoming of our study that deserves further evaluation. In addition, healthrelated quality of life was not assessed. Ideally, outcome evaluations should include parameters other than mortality. In a previous study of longterm survivors of NSCLC, high rates were found for comorbidities, distressed mood, and respiratory distress; nevertheless, health-related quality of life was good in 70% of patients. 36 In conclusion, recent improvements in survival rates in patients with cancer who are admitted to the ICU seem to extend to patients with lung cancer, including those requiring MV, and ICU support can be of benefit for selected patients. Mortality increased with the number of organ failures and severity of comorbidities; however, the strongest predictor of mortality was respiratory failure due to cancer progression. Of special note, the type of the cancer per se was not associated with mortality and for that reason should not substantially influence ICU triage decisions in patients with lung cancer.
